Parkwalk backs Moa Technology in £22.2 million Series C round

• Parkwalk Advisors invested in Moa Technology’s GBP 22.2 million Series C financing round.
• Moa is an agricultural biotechnology company focused on discovering novel mode-of-action herbicides, spun out of the University of Oxford.
• Funding targets advancing three lead programs toward commercialization, expanding early-stage herbicide discovery, further developing the Moa Amplifiers program.
• Moa reported more than 80 novel mode-of-action areas identified, with lead candidates in international field trials.
• The company expects additional equity to be supplemented by upfront and milestone payments from industry R&D partners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parkwalk Advisors Ltd published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.